Literature DB >> 2557879

Tissue expression of the tumour associated antigen CA242 in benign and malignant pancreatic lesions. A comparison with CA 50 and CA 19-9.

C Haglund1, J Lindgren, P J Roberts, P Kuusela, S Nordling.   

Abstract

The expression of a novel tumour associated antigen CA 242, defined by the monoclonal antibody C 242, was studied by immunoperoxidase staining in formalin-fixed, paraffin-embedded tissue sections from normal pancreata, pancreata with pancreatitis and benign and malignant pancreatic neoplasms. The antigenic determinant of the C 242 antibody is a sialylated carbohydrate structure, related but chemically different from tumour marker antigens CA 19-9 and CA 50. Thirty-eight of 41 (93%) well to moderately differentiated ductal adenocarcinomas of the pancreas and all cystadenocarcinomas were positive for CA 242. The staining was most intense in the apical border of the cells, and in the intraluminal mucus. Only two out of seven poorly differentiated adenocarcinomas stained, and the number of positive cells was smaller than in well differentiated carcinomas. Only occasional cells were stained in one out of five anaplastic carcinomas. Part of large ducts were positive in 91% (21/23) specimens of chronic pancreatitis. In acute pancreatitis small terminal ducts, centro-acinar cells and some large ducts stained for CA 242. In normal pancreas only a few small terminal ducts were CA 242 positive. Carcinomas always stained more strongly for CA 242 than normal pancreatic tissue adjacent to the carcinoma. The results of CA 242 are compared with those of tumour marker antigens CA 50 and CA 19-9. Serum CA 242 levels were determined in 23 of the patients with pancreatic cancer using a fluoroimmunoassay. Fifteen (65%) patients had an elevated value. There was no clear-cut correlation between the serum levels and the immunohistochemical expression of the CA 242 antigen. The expression of CA 242 in pancreatic tissue resembles that of CA 50 and is similar to CA 19-9. The antigen is expressed in serum of many patients with pancreatic cancer and, therefore, is a potential candidate for a serum tumour marker.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2557879      PMCID: PMC2247259          DOI: 10.1038/bjc.1989.377

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  19 in total

1.  Colorectal carcinoma antigens detected by hybridoma antibodies.

Authors:  H Koprowski; Z Steplewski; K Mitchell; M Herlyn; D Herlyn; P Fuhrer
Journal:  Somatic Cell Genet       Date:  1979-11

2.  Ultrastructural localization of carcinoembryonic antigen in normal intestine and colon cancer: abnormal distribution of CEA on the surfaces of colon cancer cells.

Authors:  D J Ahnen; P K Nakane; W R Brown
Journal:  Cancer       Date:  1982-05-15       Impact factor: 6.860

3.  Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19-9.

Authors:  B C Del Villano; S Brennan; P Brock; C Bucher; V Liu; M McClure; B Rake; S Space; B Westrick; H Schoemaker; V R Zurawski
Journal:  Clin Chem       Date:  1983-03       Impact factor: 8.327

4.  Immunohistochemistry of gastric carcinomas and associated diseases: novel distribution of carcinoembryonic antigen and secretory component on the surface of gastric cancer cells.

Authors:  H Nagura; Y Tsutsumi; Y Shioda; K Watanabe
Journal:  J Histochem Cytochem       Date:  1983-01       Impact factor: 2.479

5.  CEA and carbohydrate antigens in normal and neoplastic colon mucosa. An immunohistochemical study.

Authors:  Q Ouyang; M Vilien; B R Juhl; L G Larsen; V Binder
Journal:  Acta Pathol Microbiol Immunol Scand A       Date:  1987-07

6.  Concentration and localization of carbohydrate antigen 19-9 in tissues of pancreatic cancer.

Authors:  K Nishida; H Miyagawa; T Yoshikawa; M Kondo
Journal:  Oncology       Date:  1988       Impact factor: 2.935

7.  A monoclonal antibody-defined antigen associated with gastrointestinal cancer is a ganglioside containing sialylated lacto-N-fucopentaose II.

Authors:  J L Magnani; B Nilsson; M Brockhaus; D Zopf; Z Steplewski; H Koprowski; V Ginsburg
Journal:  J Biol Chem       Date:  1982-12-10       Impact factor: 5.157

8.  Comparison of a new tumour marker, CA 19-9, with alpha-fetoprotein and carcinoembryonic antigen in patients with upper gastrointestinal diseases.

Authors:  H Jalanko; P Kuusela; P Roberts; P Sipponen; C A Haglund; O Mäkelä
Journal:  J Clin Pathol       Date:  1984-02       Impact factor: 3.411

9.  Monoclonal antibodies against gastrointestinal tumour-associated antigens isolated as monosialogangliosides.

Authors:  L Lindholm; J Holmgren; L Svennerholm; P Fredman; O Nilsson; B Persson; H Myrvold; T Lagergård
Journal:  Int Arch Allergy Appl Immunol       Date:  1983

10.  Comparison of CA-50, a new tumour marker, with carcinoembryonic antigen (CEA) and alpha-fetoprotein (AFP) in patients with gastrointestinal diseases.

Authors:  P Kuusela; C Haglund; P J Roberts; H Jalanko
Journal:  Br J Cancer       Date:  1987-06       Impact factor: 7.640

View more
  14 in total

1.  Eradication of large colon tumor xenografts by targeted delivery of maytansinoids.

Authors:  C Liu; B M Tadayoni; L A Bourret; K M Mattocks; S M Derr; W C Widdison; N L Kedersha; P D Ariniello; V S Goldmacher; J M Lambert; W A Blättler; R V Chari
Journal:  Proc Natl Acad Sci U S A       Date:  1996-08-06       Impact factor: 11.205

Review 2.  Circulating blood group related carbohydrate antigens as tumour markers.

Authors:  T F Orntoft; E Bech
Journal:  Glycoconj J       Date:  1995-06       Impact factor: 2.916

3.  Monoclonal antibody C242-Pseudomonas exotoxin A. A specific and potent immunotoxin with antitumor activity on a human colon cancer xenograft in nude mice.

Authors:  W Debinski; B Karlsson; L Lindholm; C B Siegall; M C Willingham; D FitzGerald; I Pastan
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 19.456

4.  Clinical evaluation of a new serum tumour marker CA 242 in pancreatic carcinoma.

Authors:  P A Pasanen; M Eskelinen; K Partanen; P Pikkarainen; I Penttilä; E Alhava
Journal:  Br J Cancer       Date:  1992-05       Impact factor: 7.640

5.  Clinical evaluation of serum tumour marker CA 242 in non-small cell lung cancer.

Authors:  J L Pujol; E H Cooper; M Lehmann; D A Purves; M Dan-Aouta; J Midander; P Godard; F B Michel
Journal:  Br J Cancer       Date:  1993-06       Impact factor: 7.640

6.  Receiver operating characteristic (ROC) curve analysis of the tumour markers CEA, CA 50 and CA 242 in pancreatic cancer; results from a prospective study.

Authors:  P A Pasanen; M Eskelinen; K Partanen; P Pikkarainen; I Penttilä; E Alhava
Journal:  Br J Cancer       Date:  1993-04       Impact factor: 7.640

7.  A prospective study of serum tumour markers carcinoembryonic antigen, carbohydrate antigens 50 and 242, tissue polypeptide antigen and tissue polypeptide specific antigen in the diagnosis of pancreatic cancer with special reference to multivariate diagnostic score.

Authors:  P A Pasanen; M Eskelinen; K Partanen; P Pikkarainen; I Penttilä; E Alhava
Journal:  Br J Cancer       Date:  1994-03       Impact factor: 7.640

8.  Sensitivity and specificity of CA242 in gastro-intestinal cancer. A comparison with CEA, CA50 and CA 19-9.

Authors:  O Nilsson; C Johansson; B Glimelius; B Persson; B Nørgaard-Pedersen; A Andrén-Sandberg; L Lindholm
Journal:  Br J Cancer       Date:  1992-02       Impact factor: 7.640

9.  Comparative study of CA242 and CA19-9 in chronic pancreatitis.

Authors:  N Furuya; S Kawa; O Hasebe; M Tokoo; K Mukawa; S Maejima; H Oguchi
Journal:  Br J Cancer       Date:  1996-02       Impact factor: 7.640

10.  CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA.

Authors:  C Haglund; J Lundin; P Kuusela; P J Roberts
Journal:  Br J Cancer       Date:  1994-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.